Nov-01-02

12:06

From-HYSEQ INC

4085248145

T-139 P.001/009 F-500



675 Almanor Avenue Sunnyvale, CA 94086 Telephone: (408) 524-8100 Fax: (408) 524-8145

FACSIMILE TRANSMISSION COVER

DATE:	November 1, 2002
TO:	Examiner Amy DeCloux, Ph.D.
COMPANY:	United States Patent and Trademark Office
TELEPHONE NO.:	(703) 306-5821
FAX NO.:	(703) 746-4982
FROM:	Malabika Ghosh
RE:	USSN: 09/905,589
TOTAL PAGES (including cover sheet):9
COMMENTS.	

Confidentiality Note: The information contained in this facsimile message is legally privileged and confidential information that is intended only for the use of the individuals or entity listed above. If the reader of this message is not the intended recipient, you are hereby notified that any use, dissemination, distribution or reproduction of this message is strictly prohibited. If you have received this message in error, please immediately notify us by telephone and return the original message to us at the address listed above via U.S. Postal Service. Thank you.

Nov-01-02

12:06

From-HYSEQ INC

4085248145

T-139 P.002/009 F-500

Docket No. 28110-36120D

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Chadwick, et al.

Serial No:

09/905,589

Filed:

July 13, 2001

For:

METHODS AND COMPOSITIONS

RELATING TO CD39-LIKE

POLYPEPTIDES AND NUCLEIC

ACIDS

Examiner:

Amy M. DeCloux

Art Unit:

1644

CERTIFICATE OF FACSIMILE UNDER 37 CFR 1.6(d)

I hereby certify that this paper is being transmitted to the United States Patent and Trademark Office by facsimile and addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Date of Facsmilie Transmission: November 1, 2002

Type or Print Name of Person Faxing. Raquel R. Torres

Signature of Peyson

TRANSMITTAL LETTER

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Examiner DeCloux:

Enclosed are the following items for filing in the above-referenced U.S. Patent

Application:

1. Applicants' Response to a Restriction Requirement dated 10/01/02

Nov-01-02 12:06 From-HYSEQ INC 4085248145 T-139 P.003/009 F-500

The Commissioner is hereby authorized to charge payment of any fees which may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 501169. A duplicate copy of this sheet is enclosed.

Respectfully submitted

Date: November 1, 2002

By: Malabika - T. Shorth

Malabika J. Ghosh Agent for Applicants Registration No: P -52,476

Luisa Bigornia
Attorney for Applicants
Registration No.: 45,974
HYSEQ, INC.
670 Almanor Avenue
Sunnyvale, CA 94085
(408) 746 - 4536
(408) 524-8145 (Telefacsimile)

Nov-01-02

12:07

From-HYSEQ INC

4085248145

u / (0 Z

T-139 P.006/009 F-500

11/13 9nD 11/1/02

Docket No. 28110-36120D IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Chadwick, et al.

Serial No:

09/905,589

Filed:

July 13, 2001

For:

METHODS AND COMPOSITIONS

RELATING TO CD39-LIKE

POLYPEPTIDES AND NUCLEIC

ACIDS

Examiner:

Amy M. DeCloux

Art Unit:

1644

CERTIFICATE OF FACSIMILE UNDER 37 CFR 1.6(d)

I hereby certify that this paper is being transmitted to the United States Patent and Trademark Office by facsimile and addressed to the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202.

Date of Facsmilie Transmission. November 1, 2002

Type or Print Name of Person Faxing: Raquel R. Torres

Signature of Person

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

Dear Examiner DeCloux:

RESTRICTION REQUIREMENT

In response to the October 2, 2002, Restriction Requirement in the above-identified application, Applicants elect with traverse Group I, claims 19-26 and 28-29 drawn to an isolated antibody which specifically binds to a CD39L2 polypeptide having the sequence of SEQ ID NO: 2, classified in class 530, subclass 387.1. Applicants make this election without prejudice to pursuing non-elected subject matter in later applications.

Pursuant to 37 CFR 1.141, upon the allowance of the product claims, Applicants respectively reserve the right of rejoinder of Group II, claim 27, drawn to a method of detecting the presence of a CD39L2 polypeptide having the sequence of SEQ ID NO: 2, classified in class 435, subclass 7.2.